Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 7210 Frederick-Banting, Suite 100 ST-LAURENT QC H4S 2A1 |
Tel: | N/A |
Website: | https://www.reparerx.com |
IR: | See website |
Key People | ||
Lloyd M. Segal President, Chief Executive Officer, Director | Steve Forte Chief Financial Officer, Executive Vice President | Michael Zinda Executive Vice President, Chief Scientific Officer | Maria Koehler Executive Vice President, Chief Medical Officer |
Business Overview |
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company's initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor. |
Financial Overview |
For the fiscal year ended 31 December 2023, Repare Therapeutics Inc revenues decreased 61% to $51.1M. Net loss increased from $29M to $93.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects rea increase of 11% to $118.5M (expense), Stock-based Compensation in R&D increase of 32% to $13.2M (expense). |
Employees: | 179 as of Feb 16, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $51.13M as of Dec 31, 2023 |
EBITDA (TTM): | -$114.27M as of Dec 31, 2023 |
Net annual income (TTM): | -$93.80M as of Dec 31, 2023 |
Free cash flow (TTM): | -$129.10M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 42,182,177 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |